Stay updated on Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial
Sign up to get notified when there's something new on the Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial page.

Latest updates to the Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial page
- Check4 days agoNo Change Detected
- Check12 days agoChange DetectedRevision: v3.3.2 added and v3.3.1 removed as a minor site metadata update. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check19 days agoChange DetectedPubMed publications note updated to state items are automatically filled from PubMed, and the revision label changed from v3.2.0 to v3.3.1.SummaryDifference0.1%

- Check26 days agoChange DetectedThe banner notice about government funding and NIH operating status at the top of the page was removed. This does not affect the study details or eligibility information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check40 days agoChange DetectedNo significant additions or deletions were detected in the core study information; the page’s title, identifiers, conditions, eligibility criteria, interventions, and outcomes appear unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check69 days agoChange DetectedMajor update: page now includes a government funding status notice and indicates version 3.2.0, replacing the previous 3.1.0.SummaryDifference2%

- Check76 days agoChange DetectedCore terminology updated from 'Plasma cell myeloma' to 'Multiple myeloma' and the page version bumped to v3.1.0.SummaryDifference0.2%

Stay in the know with updates to Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial page.